LPCN Lipocine Inc.
$1.51▲ +3.42%
Healthcare
Other
After hours
$1.48▼ -1.99%
Oct 28, 5:02 PM ET
Volume 193.3K
Avg Volume (10D) 258.1K
Key Metrics & Fundamentals
Market Cap
$12.45M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.40 - 12.37
% vs 50 MA
-24.85%
% vs 200 MA
-62.31%
RSI-14
33.5
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.59
Free Cash Flow
-$3.03M
Gross Rev
$190,099
Gross Profit
-$1.85M
EBITDA
-$2.83M
COGS
$2.04M
Operating Exp
$990,956
Operating Income
-$2.84M
EBIT
-$2.84M
Pretax Income
-$2.62M
Net Income
-$2.62M
EPS (Diluted)
-0.32
Price & Volume History
Loading chart…
Recent News
Here's Why You Should Add LPCN Stock to Your Portfolio Now
Zacks · Oct 8, 2026 9:57 AM ET
Top Midday Gainers
MT Newswires · Oct 7, 2026 1:27 PM ET
BC-Most Active Stocks
Associated Press · Oct 7, 2026 10:30 AM ET
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
InvestorsHub · Oct 7, 2026 10:01 AM ET
Lipocine stock surges 30% on Health Canada drug approval
Investing.com · Oct 7, 2026 9:24 AM ET
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
Stocktwits · Oct 7, 2026 8:44 AM ET
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
PR Newswire · Oct 7, 2026 8:00 AM ET
Top Premarket Gainers
MT Newswires · Oct 7, 2026 7:08 AM ET
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Zacks · Sep 23, 2026 12:00 PM ET
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
PR Newswire · Sep 14, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LPCN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.